This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Unity (UNX) Down on Disappointing Results From Wet AMD Study
by Zacks Equity Research
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.
All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy
by Zacks Equity Research
UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now
by Zacks Equity Research
UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.
Unity Biotechnology (UBX) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Unity Biotechnology (UBX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Unity Shares Slump 66% As Lead Arthritis Drug Fails in Study
by Zacks Equity Research
Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.
Moving Average Crossover Alert: Unity Biotechnology
by Zacks Equity Research
Unity Biotechnology, Inc. (UBX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Will Unity Biotechnology Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Unity Biotechnology
Unity Biotechnology's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Unity Biotechnology.
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
by Swarup Gupta
Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.
UNITY (UBX) Soars: Stock Adds 5.1% in Session
by Zacks Equity Research
UNITY (UBX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Unity (UBX) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Unity (UBX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for August 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 16th: